Kazia Therapeutics Limited ADRKZIA
Price$9.47

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $27.6K0.0% YoYTTM through 31 Dec 2025
Net Income -$13.6MTTM through 31 Dec 2025
Free Cash Flow -$13.3MTTM through 31 Dec 2025

Margins

Current
Gross Margin0.0%
Operating Margin-45,469.2%
Net Margin-49,290.5%

Returns

-43.7%ROE
-28.6%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.87x
Net Debt-$46.3Mnet cash position
Cash & Equivalents$69.5M

Quality Metrics

Piotroski F-Score4 / 9
FCF Margin-48,140.7%

Multi-Year Trend

Revenue
'16'17'18'23'24'25
FY2025: $42K
Diluted EPS
'17'18'19'20'21'22'23
FY2023: $-0.11

Dividend

No dividend

Capital Allocation

Capex Intensity43.5%
Financials converted at 1.4930 from AUD.
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.